A total of 30 patients with chronic hepatitis C (HCV) thrombocytopenia (TP) and 20 healthy controls were studied. Both groups were subjected to complete medical history, clinical examination in addition to assessment of hepatitis markers: level of thrombopoietin (Tpo), Geimsa-stained bone marrow smears, and in vitro short-term megakaryocytic progenitors culture (CFU-MK). Serum Tpo level was significantly elevated in patients with TP HCV. Short-term CFU-MK showed an evident depression in the colony-forming unit—megakaryocyte (CFU-meg). There is a positive correlation between the number of CFU-meg and the platelet count and between serum Tpo level and prothrombin time, transaminase, albumin, and the Child Pugh score of liver disease; a negative correlation between serum Tpo level and the number of CFU-meg and between serum Tpo level and the platelet count. Thus, the level of Tpo could be an indicator of intact functional response of the hepatocytes.
Hoffman R.Regulation of megakaryocytopoiesis. Blood. 1989;74(4):1196-1212.
2.
Berthier R., Valiron O., Schweitzer A., Marguerie G.Serum-free medium allows the optimal growth of human megakaryocyte progenitors compared with human plasma supplemented cultures: role of TGF beta. Stem cells. 1993;11(2):120-129.
3.
Okubo M., Shiota G., Kawasaki H.Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci. 2000;99(3):207-214.
4.
Bruno E., Briddell R., Hoffman R.Effect of recombinant and purified hematopoietic growth factors on human megakaryocyte colony formation. Exp Hematol. 1988;16(5):371-377.
5.
Imai T., Koike K., Kubo T., et al. Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood. 1991;78(8):1969-1974.
6.
Bruno E., Briddell RA, Cooper RJ, Hoffman R.Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells . Exp Hematol. 1991;19(5):378-381.
7.
Kaushansky K.Thrombopoietin: the primary regulator of platelet production. Blood. 1995;86(2):419-431.
8.
Gibson FM, Marsh JC, Gordon-Smith ECIn vitro revelations of aplastic anemia. Int J Cell Cloning.1992;10(5):262-268.
9.
Teramura M., Katahira J., Hoshino S., Motoji T., Oshimi K., Mizoguchi H.Clonal growth of human megakaryocyte progenitors in serum-free cultures: effect of recombinant human interleukin 3. Exp Hematol. 1988;16(10):843-848.
10.
Clarke E., Miller CL, Mantie D., et al. Standardization of samples and protocols for proficiency testing of hematopoietic progenitor enumeration. Exp Hematol. 1999;27:114a.
11.
Hogge D., Fanning S., Bockhold K., et al. Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free agarose assay. Br J Haematol. 1997;96(4):790-800.
Peck-Radosavljevic M., Wichlas M., Zacherl J., et al. Thrombopoietin induces rapid resolution of thrombocytopenia after ortho-topic liver transplantation through increased platelet production. Blood. 2000;95(3):795-801.
14.
Vyzantiadis T., Theodoridou S., Giouleme O., Evgenidis N., Vyzantiadis A., Garipidou V.Serum thrombopoietin levels in thrombocytopenic patients with liver cirrhosis. Hematologica. 2002;87(8):890-891.
15.
Parker LSThrombocytopenia. In: Lee RG, Foerster J, Lukens J, et al., eds. Wintrobe’s Clinical Hematology. 10th ed, Vol 2. Baltimore: Williams & Wilkins; 1999:1579-1582.
16.
Hillman RS, Ault KAThrombocytopenia. In: Hematology in Clinical Practice: A Guide to Diagnosis and Management. 2nd ed. New York: McGraw-Hill; 1998:437-445.
17.
Warkentin TE , Kelton JGThrombocytopenia. In: Irwin RS, Cerra FB , Rippe JM, eds. Irwin and Rippe’s Intensive Care Medicine. 4th ed, Vol II. Philadelphia, PA: Lippincott Raven; 1999: 1338-1349.
18.
Long W., Hoffman RMThrombocytopoiesis. In: Hoffman R , Benz EJ Jr, Shattil SJ , Furie B , McGlave P. eds. Hematology, Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone ; 2000:245-260.
19.
Giannini E. , Borro P., Botta F., et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol. 2002;37(5):572-577.
20.
Schoffski P. , Tacke F., Trautwein C., et al. Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease. Liver. 2002;22(2):114-120.
21.
Reinhold J.Determination of serum total protein, albumin and globulin fractions by the biuret method. In: Varley H, Gowenlock AH, Bell M , eds. Practical Clinical Biochemistry . 5th ed, Vol I. London: William Heinemann; 1980 :45-47.
22.
King KJ, Armstrong ALCalcium, phosphorus and phosphatase. In: Varley H, ed. Practical Clinical Biochemistry. 4th ed. New Delhi: CBS Publishers; 1988:457-461.
23.
Blood, Vol. 92 No. 9 (November 1), 1998: pp. 3328-333Sansonno D., Lotesoriere C., Comacchiulo V.Hepatitis C virus infection involves CD34(±) hematopoietic progenitor cells in 8 hepatitis C virus chronic carriers. Blood. 1998;92(2):3328-3337.
24.
Koruk M., Onuk MD, Akcay F., Savas MCSerum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts . Hepatogastroenterology. 2002;49(48):1645-1648.
25.
Levin M.Acute hypersplenism and thrombocytopenia: a new presentation of disseminated mycobacterial infection in patients with acquired immunodeficiency syndrome . Acta Haematol. 1994; 91(1):28-31.
26.
Espanol I., Gallego A., Enriquez J., et al. Thrombocytopenia associated with liver cirrhosis and hepatitis C virus infection: role of thrombopoietin. Hepatogastroenterology . 2000;47(35): 1404-1406.
Iga D., Tomimatsu M., Endo H., Ohkawa S., Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-a therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol. 2005 ;75(5):417-423.
29.
Gu J., Lu L., Xu R., Chen X.Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Chin Med J (Engl) . 2002;115(7):983-986.
30.
Niitsu Y., Sakamaki S., Hirayama Y., et al. TGF-B induces thrombopoietin from bone marrow stromal cells which stimulates the expression of TGF-B receptor on megakaryocytes and in turn renders them susceptible to suppression by TGF-B itself with high specificity . Blood. 1999;94(6):1961-1970.
31.
Kaufman DS, Hanson ET, Lewis RL, Auerbach R., Thomson JAHematopoietic colony forming cells derived from human embryonic stem cells . Proc Natl Acad Sci U S A. 2001;98(19): 10716-10721.
32.
Bruno S., Gammaitoni L., Gunetti M., et al. Different growth factor requirements for the ex vivo amplification of transplantable human cord blood cells in a NOD/SCID mouse model. J Biol Regul Homeost Agents. 2001;15(1):38-48.
33.
Lazzari L., Henschiler R., Lecchi L., Rebulla P., Mertelsmann R., Sirchia G.Interleukin-6 and interleukin-11 act synergistically with thrombopoietin and stem cell factor to modulate ex vivo expansion of human CD41+ and CD61+ megakaryocytic cells. Haematologica. 2000;85(1):25-30.
34.
Hodohara KN , Fuji N., Yammamoto N., Kaushansky K.Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood. 2000;95(3):769-775.
35.
Tarner KJ, Nebevn S., Weich N., Schaub RG, Goldman SJThe role of recombinant interleukin 11 in megakaryocytopoiesis. Stem Cells. 1996;14(suppl 1):53-61.
36.
Li K., Yang M., Lam AC, Yau FW, Yuen PMEffects of Flt-3 ligand in combination with TPO on the expansion of megakaryocytic progenitors. Cell Transplant. 2000;9(1):25-131.
37.
Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood . 2004;103(2):500-506.
38.
Ogawa M.Effects of hemopoietic growth factors on stem cells in vitro. Hematol Oncol Clin North Am. 1989;3(3):453-464.
39.
Cox CV, Kililck SB, Patel S., et al. In vitro proliferation and differentiation of megakaryocytic progenitors in patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria, and the myelodysplastic syndromes. Stem Cells. 2000;18(6): 428-434.
40.
Kaushansky K.Thrombopoietin. N Engl J Med.1998;339(11): 746-754.
41.
Jelkmann W.The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol . 2001;13(7):791-801.
42.
Weksler BBReview article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther . 2007;26(suppl 1):13-19.
43.
Vardareli E. , Saricam T., Demirustu C., Gulbas Z. Soluble P selectin levels in chronic liver disease: relationship to disease severity . Hepatogastroenterology . 2007;54(74):466-469.
44.
Alyan O., Kacmaz F., Ozdemir O., et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J. 2008;72(12): 1960-1965.
45.
Berndt MC, Phillips DRPlatelet membrane proteins: composition and receptor function. In: Gordon JL, ed. Platelet in Biology and Pathology. Amsterdam: Elsevier/North Holland Biomedical Press; 1981:43-75.
46.
Lowe GDO , Forbes CDBlood rheology and thrombosis. In: Prentice CRM, ed. Clinics in Haematology . Vol 10. London: WB Saunders Co Ltd; 1981:343-367.
47.
Mikhailidis DP, Barradas MA, Maris A., Jeremy JY, Dandona P.Fibrinogen-mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. J Clin Pathol. 1985;38(10):1166-1171.
48.
Zimmermann T., Böcher WO, Biesterfeld S., et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribiviran in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007;20(7):583-590.
49.
Nudo CG, Wong P., Hilzenrat N., Deschênes M.Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol. 2006 ;20(9):589-592.
50.
Curry MP, Afdhal NHUse of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver Dis.2005;9(3):439-451, vii.
51.
Van Thiel DH , George M., Fareed J.Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease . Thromb Haemost. 2001;85(4):667-670.
52.
Colucci M., Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology. 2003;38(1): 230-237.
53.
Tacke F., Fiedler K., von Depka M., et al. Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. Liver Int. 2006;26(2):173-181.
54.
Federico A. , Filippelli A., Falciani M., et al. Platelet aggregation is affected by nitrosothiols in patients with chronic hepatitis: in vivo and in vitro studies . World J Gastroenterol. 2007;13(27): 3677-3683.
55.
Wendling F.Thrombopoietin: its role from early hematopoiesis to platelet production. Haematologica. 1999 ;84(2):158-166.
56.
Espanol I., Hernandez A., Muniz-Diaz E., Ayats R., Pujol-Moix N.Usefulness of thrombopoietin in the diagnosis of thrombocytopenia . Haematologica. 1999;84(7):608-613.
57.
Kuefer MU, Wang WC, Head DR, et al. Thrombopoietin level in young patients is related to megakaryocyte frequency and platelet count. J Pediatr Hematol Oncol. 1998;20(1):36-43.
58.
Tsui JI, Whooley MA, Monto A., Seal K., Tien PC, Shlipak M.Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. J Card Fail.2009 ;15(5): 451-456.
59.
Guiltinan AM , Kaidarova Z., Custer B., et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors . Am J Epidemiol. 2008;167(6):743-750.
60.
Lenci I., Piccolo P., Francioso S., Di Paolo D., Galante A., Angelico M.Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels. Dig Liver Dis. 2008;40(9):785-790.
61.
Elsurer R., Afsar B., Sezer S., Arat Z., Ozdemir FN, Haberal M.Malnutrition inflammation score is associated with coronary artery disease in hepatitis C virus-infected hemodialysis patients. Eur J Clin Nutr. 2008;62(12):1449-1454.
62.
Tosta C., Ladeira R., Guz B., Pimenta J.Cardiac morphofunctional injuries in patients with hepatitis C virus: doppler echocardiographic evaluation. Arq Bras Cardiol. 2006;87(5):623-627.
63.
Moritani M. , Adachi K., Arima N., et al. A study of arteriosclerosis in healthy subjects with HBV and HCV infection. J Gastroenterol. 2005;40(11):1049-1053.
64.
Momiyama Y. , Ohmori R., Kato R., Taniguchi H., Nakamura H., Ohsuzu F.Lack of any association between persistent hepatitis B or C virus infection and coronary artery disease . Atherosclerosis. 2005;181(1):211-213.
65.
Kcomt W., Nahavandi AA, Myaing M., Alkhalil C., Stein D. Hepatitis C and the heart: to beat or not to beat. Int J Cardiol. 2004;96(2):147-149.
66.
Vassalle C. , Masini S., Bianchi F., Zucchelli GCEvidence for association between hepatitis C virus seropositivity and coronary artery disease . Heart . 2004;90(5):565-566.
67.
Haji SA, Starling RC, Avery RK, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant. 2004; 23(3):277-283.
68.
Tsiara S., Elisaf M., Jagroop IA, Mikhailidis DPPlatelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost. 2003;9(3):177-190.
